Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL5665313 | 0.82 | TSHR (0.43) | TSHRNAPRTTDP1PTGS1PTGS2 | |
| Pyridine SCHEMBL9342358 | 0.82 | TSHR (0.43) | TSHRNAPRTTDP1PTGS1PTGS2 | |
| SCHEMBL31247237 | 0.81 | — | — | |
| SCHEMBL16998538 | 0.81 | — | — | |
| SCHEMBL1332156 | 0.81 | — | — | |
| SCHEMBL38490 | 0.81 | — | — | |
| SCHEMBL2744387 | 0.81 | USP2 (0.39) | TSHR | |
| Pyridine SCHEMBL6282630 | 0.79 | TSHR (0.36) | TSHRNAPRTTDP1 | |
| SCHEMBL1377186 | 0.78 | USP2 (0.37) | TSHR | |
| Hydrogen Sulfide SCHEMBL7995255 | 0.78 | USP2 (0.37) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873289-B2 | Pyrazole compounds and preparation thereof | MyoKardia, Inc. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20210053940-A1 | PYRAZOLE COMPOUNDS AND PREPARATION THEREOF | SRF LIMITED (IN) | 2021-02-25 | — | — | US | disclosed |
| EP-3746434-A1 | PYRAZOLE COMPOUNDS AND PREPARATION THEREOF | MyoKardia, Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019150392-A1 | PYRAZOLE COMPOUNDS AND PREPARATION THEREOF | SRF LIMITED (IN) | 2019-08-08 | — | — | WO | disclosed |
| EP-3055030-A1 | AMPHOTERICIN B DERIVATIVES WITH IMPROVED THERAPEUTIC INDEX | The Board of Trustees of the University of Illinois (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015054148-A1 | AMPHOTERICIN B DERIVATIVES WITH IMPROVED THERAPEUTIC INDEX | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-04-16 | — | — | WO | disclosed |
| US-6974870-B2 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHAMACEUTICALS, INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20040180922-A1 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873289-B2 | Pyrazole compounds and preparation thereof | TNNI3, TNNT2, HNRNPL | TSHR 2417/4885NAPRT 4508/4885TDP1 2925/4885 |
| US-20210053940-A1 | PYRAZOLE COMPOUNDS AND PREPARATION THEREOF | TNNI3, TNNT2, HNRNPL | TSHR 2417/4885NAPRT 4508/4885TDP1 2925/4885 |
| US-20040180922-A1 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | NFKBIA, IKBKB, CHUK | TSHR 2384/4885NAPRT 1508/4885TDP1 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.